![Nicolas Poirier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicolas Poirier
Geen lopende functies
Vermogen: 4 M $ op 30-06-2026
Profiel
Nicolas Poirier worked as a Project Manager at Effimune SA. From 2016 to 2026, Dr. Poirier worked at OSE Immunotherapeutics SA, serving as Chief Scientific Officer from 2025 to 2026.
Dr. Poirier completed undergraduate studies at Centre d'Etudes Supérieures de Techniques Industrielles and graduate degrees at the University of Nantes and Louis Pasteur University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-09-2025 | 1.131.603 ( 4,99% ) | 4 M $ | 30-06-2026 |
Eerdere bekende functies van Nicolas Poirier
| Bedrijven | Functie | Einde |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Algemeen Directeur | 02-10-2025 |
Effimune SA
 Effimune SA BiotechnologyHealth Technology Engages in the research and development of drugs for transplantation and immune-mediated diseases | Corporate Officer/Principal | - |
Opleiding van Nicolas Poirier
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
36
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
University of Nantes
 University of Nantes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Effimune SA
Effimune SA BiotechnologyHealth Technology Engages in the research and development of drugs for transplantation and immune-mediated diseases | Health Technology |
Centre d'Etudes Supérieures de Techniques Industrielles
 Centre d'Etudes Supérieures de Techniques Industrielles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
